

<https://helda.helsinki.fi>

Sex differences in COVID-19 mortality risk in patients on kidney function replacement therapy

Vart, Priya

2022-10-26

Vart, P, Duivenvoorden, R, Adema, A, Covic, A, Finne, P, Heijtkink-ter Break, N, Laine, K, Noordzij, M, Schouten, M, Jager, K J & Gansevoort, R T 2022, ' Sex differences in COVID-19 mortality risk in patients on kidney function replacement therapy ', Scientific Reports, vol. 12, no. 1, 17978. <https://doi.org/10.1038/s41598-022-22657-4>

<http://hdl.handle.net/10138/351346>

<https://doi.org/10.1038/s41598-022-22657-4>

cc_by

publishedVersion

Downloaded from Helda, University of Helsinki institutional repository.

This is an electronic reprint of the original article.

This reprint may differ from the original in pagination and typographic detail.

Please cite the original version.



OPEN

Sex differences in COVID-19 mortality risk in patients on kidney function replacement therapy

Priya Vart^{1,2✉}, Raphaël Duivenvoorden³, Aaltje Adema⁴, Adrian Covic^{5,6}, Patrik Finne⁷, Nicole Heijtkink-ter Braak⁸, Kaisa Laine⁹, Marlies Noordzij¹, Marcel Schouten¹⁰, Kitty J. Jager^{11,12}, Ron T. Gansevoort¹ & ERACODA Collaborators*

In the general population with COVID-19, the male sex is an established risk factor for mortality, in part due to a more robust immune response to COVID-19 in women. Because patients on kidney function replacement therapy (KFRT) have an impaired immune response, especially kidney transplant recipients due to their use of immunosuppressants, we examined whether the male sex is still a risk factor for mortality among patients on KFRT with COVID-19. From the European Renal Association COVID-19 Database (ERACODA), we examined patients on KFRT with COVID-19 who presented between February 1st, 2020, and April 30th, 2021. 1204 kidney transplant recipients (male 62.0%, mean age 56.4 years) and 3206 dialysis patients (male 61.8%, mean age 67.7 years) were examined. Three-month mortality in kidney transplant recipients was 16.9% in males and 18.6% in females ($p = 0.31$) and in dialysis patients 27.1% in males and 21.9% in females ($p = 0.001$). The adjusted HR for the risk of 3-month mortality in males (vs females) was 0.89 (95% CI 0.65, 1.23, $p = 0.49$) in kidney transplant recipients and 1.33 (95% CI 1.13, 1.56, $p = 0.001$) in dialysis patients ($p_{\text{interaction}} = 0.02$). In a fully adjusted model, the aHR for the risk of 3-month mortality in kidney transplant recipients (vs. dialysis patients) was 1.39 (95% CI 1.02, 1.89, $p = 0.04$) in males and 2.04 (95% CI 1.40, 2.97, $p < 0.001$) in females ($p_{\text{interaction}} = 0.02$). In patients on KFRT with COVID-19, the male sex is not a risk factor for mortality among kidney transplant recipients but remains a risk factor among dialysis patients. The use of immunosuppressants in kidney transplant recipients, among other factors, may have narrowed the difference in the immune response to COVID-19 between men and women, and therefore reduced the sex difference in COVID-19 mortality risk.

In the general population with COVID-19, men exhibit a higher risk of mortality compared with women. In a meta-analysis of over 3 million reported cases of COVID-19 globally, men were reported to have an almost 40% higher likelihood of mortality despite a similar likelihood of having confirmed COVID-19 when compared with women¹. Previously it has been shown that women demonstrate a more robust immune response to COVID-19 compared with men and this is suggested to be one of the contributing factors to the observed sex differences in mortality risk². This line of reasoning also suggests that in an immunocompromised patient population with COVID-19, the sex difference in mortality risk is narrowed or eliminated.

Patients on kidney function replacement therapy (KFRT) have an impaired immune response, especially kidney transplant recipients due to their use of immunosuppressants. Among kidney transplant recipients with COVID-19, some studies indeed showed no sex difference in mortality^{3,4}. However, others demonstrated a higher risk of mortality in men compared with women⁵. Likewise, among dialysis patients with COVID-19, prior studies

¹Department Internal Medicine, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9713 GZ Groningen, The Netherlands. ²Department of Clinical Pharmacy & Pharmacology, University Medical Center Groningen, Groningen, The Netherlands. ³Department of Nephrology, Radboud University Medical Center, Nijmegen, The Netherlands. ⁴Medisch Centrum Leeuwarden, Leeuwarden, The Netherlands. ⁵Grigore T Popa University of Medicine and Pharmacy, Iasi, Romania. ⁶Dr Ci Parhon Hospital, Iasi, Romania. ⁷Helsinki University Central Hospital and Helsinki University, Helsinki, Finland. ⁸Zuyderland Ziekenhuis, Sittard-Geleen, The Netherlands. ⁹Satakunta Central Hospital, Pori, Finland. ¹⁰Tergooi Medical Center, Hilversum, The Netherlands. ¹¹ERA Registry, Amsterdam UMC Location University of Amsterdam, Medical Informatics, Meibergdreef 9, Amsterdam, The Netherlands. ¹²Amsterdam Public Health Research Institute, Quality of Care, Amsterdam, The Netherlands. *A list of authors and their affiliations appears at the end of the paper. ✉email: p.vart@umcg.nl

reported no to an almost twofold increased risk of mortality in men compared with women^{6–9}. Importantly, these studies were in general relatively small in size and/or lacked information on key covariates, and therefore lacked power and careful control of these covariates when assessing sex-mortality relationships. Moreover, it remains unclear whether the sex difference in mortality risk differs between kidney transplant recipients and dialysis patients. A better understanding of potential sex-based differences in mortality risk among patients on KFRT with COVID-19 may guide more specific interventions and management of COVID-19 by incorporating sex considerations¹⁰.

Therefore, we examined whether sex is associated with the risk for mortality among patients on KFRT with COVID-19. For this study, we used data from the European Renal Association COVID-19 Database (ERACODA), the largest European database with detailed information on patient demographics, comorbidities, symptoms, laboratory results, and prospective follow-up for mortality in patients on KFRT with COVID-19.

Materials and methods

Study design and participants. ERACODA was established in March 2020 to study the prognosis and risk factors for mortality among kidney failure patients with COVID-19. Details of the database and the study design have been published previously¹¹. Briefly, adult (≥ 18 years) patients either on dialysis (hemodialysis or peritoneal dialysis) or living with a functioning kidney allograft, who were diagnosed with COVID-19 based on a positive result on a real-time polymerase chain reaction assay or rapid antigen test of nasal and/or pharyngeal swab specimens, and/or compatible findings on CT scan or chest X-ray of the lungs were included. Data were voluntarily reported on outpatients and hospitalized patients by physicians responsible for their care. The database currently involves the cooperation of approximately 225 physicians representing over 140 centers in about 35 countries, mostly in Europe.

The database is hosted at the University Medical Center Groningen, The Netherlands. Data is recorded using REDCap software (Research Electronic Data Capture, Vanderbilt University Medical Center, Nashville, TN, USA) for data collection¹². Patient information is stored pseudonymized. The study was approved by the Institutional Review Board (IRB) of the University Medical Center Groningen (Netherlands). Since the study did not involve identifiable private information and was observational in nature, a waiver of informed consent was granted by IRB of the University Medical Center Groningen in The Netherlands. Participating centers obtained study approval and waiver of consent from IRBs of their respective institute. All methods were performed per the relevant guidelines and regulations. The clinical and research activities being reported are consistent with the Principles of the Declaration of Istanbul as outlined in the 'Declaration of Istanbul on Organ Trafficking and Transplant Tourism'. No organs were procured from prisoners.

Detailed information was collected on patient characteristics (age, sex, race/ethnicity, height, weight, frailty, comorbidities, hospitalization, and medication use) and COVID-19-related characteristics (reason for COVID-19 screening, symptoms, vital signs, and laboratory test results) at presentation. Frailty was assessed using the Clinical Frailty Score developed by Rockwood et al.¹³. Obesity was defined as a body mass index ≥ 30 kg/m². For the analysis, all patients who presented between February 1st, 2020, and April 30th, 2021, and for whom information on sex, the date of presentation, type of renal replacement therapy, and 3-month mortality was available were included (Fig. S1). The primary outcome was 3-month mortality. The secondary outcome was 28-day mortality.

Statistical analysis. Baseline characteristics are presented by sex (male/female) for dialysis patients and kidney transplant recipients, separately. Continuous data are presented as mean (standard deviation (SD)) or as median (interquartile interval (IQI)) in case of a non-Gaussian distribution of data. Categorical data are presented as numbers (percentages). Baseline characteristics were compared between men and women using the independent sample t-test (in case of Gaussian distribution) or the Mann–Whitney U-test (in case of non-Gaussian distribution) for continuous variables and the Pearson Chi-2 test for categorical variables. The standardized difference in baseline characteristics between men and women for both continuous and categorical variables was also calculated. Standardized difference estimates are based only on sample statistics and are not directly influenced by sample size¹⁴. A standardized difference of 0.15 or more was used to indicate a relevant difference in baseline characteristics between men and women¹⁵.

To investigate the association between sex and mortality risk, hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated for the association of sex (male versus female (reference)) with 3-month mortality using Cox proportional-hazards regression models. Multiple models were constructed to account for factors that may explain any observed difference in 3-month mortality between men and women. Model 1 was a crude (unadjusted) model. In Model 2 we adjusted for age (continuous) and clinical frailty score (Continuous). In Model 3, given sex-related differences in access to care^{16–18}, we additionally adjusted for the reason for COVID-19 screening (symptoms-based screening/positive COVID-19 contact or routine screening). Model 4 was further adjusted for factors known to be associated with COVID-19 outcome, i.e. smoking (never, current, former), obesity (yes/no), hypertension (yes/no), diabetes (yes/no), heart failure (yes/no), chronic lung disease (yes/no), coronary artery disease (yes/no), and auto-immune disease (yes/no)¹⁹. In the final model (Model 5), we additionally adjusted for the duration of KFRT (years) and estimated the glomerular filtration rate. In dialysis patients, eGFR was assumed to be 0 for those with residual diuresis ≤ 200 mL/day and 5 mL/min/1.73 m² for those with residual diuresis > 200 mL/day²⁰. The proportional-hazards assumption was investigated by comparing a model with and without the interaction of log(time) with individual covariates. Cumulative incidence was plotted for 3-month mortality by sex. The Kolmogorov–Smirnov test was used to compare cumulative incidence between men and women.

To assess the robustness of the association between sex with mortality, we performed several additional analyses. First, to assess the consistency of our results across key subgroups we investigated results by subgroups

of age ($< 65/\geq 65$ years), the reason for COVID-19 screening (symptoms-based screening/positive COVID-19 contact or routine screening), frailty ($< 4/\geq 4$), obesity (yes/no), hypertension (yes/no), and diabetes (yes/no). Second, assuming immunosuppressant use is among the main factors contributing to excess mortality in kidney transplant recipients compared with dialysis patients and immunosuppressant use affects men and women differently for the risk of mortality in presence of COVID-19, we investigated the association of type of KFRT with mortality by sex. Third, to further account for potential differences in access to care among men and women, we investigated the association between sex and 3-month mortality when starting follow-up from the date of symptom(s) onset. Fourth, to investigate potential sex differences in relatively short-term mortality risk, we examined the association of sex with 28-day mortality instead of 3-month mortality. Fifth, we investigated sex differences in mortality risk by hospitalization and intensive care unit admission status. Finally, to account for the potential influence of between-country differences on the sex-mortality relationship, we constructed a random intercept model with the country as a random factor in a multilevel mixed-effects parametric survival model.

All analyses were performed using Stata version 17.0 (College Station, TX). A 2-sided p -value less than 0.05 was adopted to indicate statistical significance.

Results

Baseline characteristics. Baseline characteristics of the study population by type of KFRT and sex are reported in Table 1. Among a total of 1204 kidney transplant recipients (mean age 56.4 years), 747 (62.0%) were men and 457 (38%) were women. Men on average had lower body mass index and clinical frailty scores compared with women, whereas the prevalence of prior smoking, hypertension, and coronary artery disease was higher among men. The prevalence of auto-immune diseases was higher among women compared with men. Presenting symptoms were largely comparable between men and women except that women more often reported nausea or vomiting.

Among 3206 dialysis patients (mean age 67.7 years), 1981 (61.8%) were men and 1225 (38.2%) were women. Similar to kidney transplant recipients, the prevalence of prior smoking and chronic artery disease was higher among men compared with women and again the prevalence of auto-immune diseases was higher among women. Men more often had fever at presentation and the level of C-reactive protein was also higher among men compared with women.

Three-month mortality. In kidney transplant recipients, 16.9% of men and 18.6% of women died within 3 months of presentation ($p=0.31$). Cumulative mortality incidence was similar between men and women ($p=0.57$) (Fig. S2). In a crude model, the HR for the risk of 3-month mortality in men (vs women) was 0.90 (95% CI 0.68, 1.18; $p=0.43$). In the final multivariable model adjusted model (Model 5), the HR for the risk of 3-month mortality in men vs women was 0.89 (95% CI 0.65, 1.23; $p=0.49$) (Table 2; Fig. 1).

In dialysis patients, 27.1% of men and 21.9% of women died within 3 months of presentation ($p=0.001$). Cumulative mortality incidence was higher in men compared with women ($p<0.001$) (Fig. S2). In a crude model, the HR for the risk of 3-month mortality in men vs women was 1.27 (95% CI 1.10, 1.47; $p=0.001$) and in the fully adjusted model, it was 1.33 (95% CI 1.13, 1.56, $p=0.001$) in dialysis patients (Table 2; Fig. 1).

The interaction between sex and type of KFRT for mortality risk was statistically significant (p for interaction = 0.02). No violation of the proportional hazards assumption was noted in the fully adjusted model for kidney transplant recipients nor for dialysis patients (p -value for difference between the model with and without interaction between log(time) and covariates being 0.41 in case of kidney transplant recipients and 0.75 in case of dialysis patients).

Additional analyses. The observed association between sex and 3-month mortality risk in kidney transplant recipients and dialysis patients was consistent across all examined subgroups except across the subgroup of obesity (no/yes) in dialysis patients where the association was particularly evident among non-obese patients (Fig. 2).

In a fully adjusted model, the HR for the risk of 3-month mortality in kidney transplant recipients (vs. dialysis patients) was 1.39 (95% CI 1.02, 1.89, $p=0.04$) among men and was 2.04 (95% CI 1.40, 2.97, $p<0.001$) among women (p for interaction = 0.02) (Table 3). When the follow-up period was considered to start from the date of symptom(s) onset, the association between sex and 3-month mortality remained statistically non-significant among kidney transplant recipients and statistically significant among dialysis patients (Table S1). When investigating the association between sex and mortality for 28-day mortality, by hospitalization status or by ICU admission status, results were essentially similar to our main findings (Tables S2, S3, and S4 respectively). Finally, the observed association between sex and 3-month mortality risk in kidney transplant recipients and dialysis patients remained unchanged when accounting for potential between-country differences in the relationship between sex and mortality (Table S5).

Discussion

In this large study of patients on KFRT with COVID-19, men were at higher risk of mortality in dialysis patients, whereas mortality risk was similar in males and females in kidney transplant recipients. The observed association between sex and mortality risk in dialysis and transplant patients was consistent across key subgroups except across subgroups according to body mass index in dialysis patients where the increased risk of mortality in men was particularly high among non-obese patients. Importantly, when men and women were investigated separately for the association of type of KFRT with mortality, there was less difference in the adjusted risk of mortality between kidney transplant recipients and dialysis patients among men compared with women.

	Kidney transplant recipients (N = 1204)				Dialysis patients (N = 3206)			
	Women (N = 457)	Men (N = 747)	p-value	Std. difference	Women (N = 1225)	Men (N = 1981)	p-value	Std. difference
Patient characteristics								
Age, (years)	55.7 (14.1)	56.9 (13.7)	0.16	- 0.08	67.5 (14.6)	67.8 (14.2)	0.67	- 0.02
Body Mass Index, (kg/m ²)	27.5 (5.8)	26.8 (4.3)	0.02	0.16	27.2 (6.5)	26.6 (4.8)	0.01	0.15
Caucasians, n (%)	354 (77.5)	616 (82.5)	0.07	0.10	978 (79.8)	1641 (82.8)	0.001	0.14
Tobacco use, n (%)			<0.001	0.50			<0.001	0.61
Current	12 (2.6)	35 (4.7)			53 (4.3)	154 (7.8)		
Prior	53 (11.6)	206 (27.6)			111 (9.1)	501 (25.3)		
Never	287 (62.8)	311 (41.6)			618 (50.4)	510 (25.7)		
Unknown	105 (23.0)	195 (26.1)			443 (36.2)	816 (41.2)		
Reason for screening ^a , n(%)			0.48	0.10			0.41	0.07
Symptoms only	332 (72.6)	533 (71.3)			580 (47.3)	978 (49.4)		
Symptoms and COVID + contact	49 (10.7)	85 (11.4)			146 (11.9)	212 (10.7)		
COVID + contact only	19 (4.2)	29 (3.9)			113 (9.2)	160 (8.1)		
Routine	16 (3.5)	15 (2.0)			104 (8.5)	469 (8.2)		
Clinical frailty scale, AU	3.2 (1.6)	2.8 (1.4)	<0.001	0.28	4.2 (1.8)	3.9 (1.8)	<0.001	0.15
Comorbidities, n (%)								
Hypertension	352 (77.0)	631 (84.5)	0.001	- 0.19	969 (79.2)	1607 (81.1)	0.18	- 0.05
Diabetes mellitus	130 (28.6)	249 (33.4)	0.08	- 0.10	494 (40.4)	871 (44.0)	0.04	- 0.07
Coronary artery disease	49 (10.8)	162 (21.7)	<0.001	- 0.30	354 (28.9)	742 (37.6)	<0.001	- 0.18
Heart failure	34 (7.5)	68 (9.1)	0.32	- 0.06	281 (23.0)	464 (23.5)	0.73	- 0.01
Chronic lung disease	33 (7.3)	54 (7.2)	0.99	0.00	136 (11.1)	274 (13.9)	0.02	- 0.08
Active malignancy	18 (4.0)	29 (3.9)	0.96	0.00	50 (4.1)	135 (6.8)	0.001	- 0.12
Auto-immune disease	34 (7.5)	27 (3.9)	0.01	0.15	62 (5.1)	60 (3.0)	0.004	0.10
Primary kidney disease, n (%)								
Primary glomerulonephritis	66 (14.5)	140 (19.1)	0.04	- 0.12	120 (10.2)	237 (12.6)	0.04	- 0.08
Pyelonephritis	15 (3.3)	13 (1.8)	0.09	0.10	23 (1.9)	25 (1.3)	0.18	0.05
Interstitial nephritis	20 (4.4)	19 (2.6)	0.09	0.10	35 (3.0)	51 (2.7)	0.69	0.01
Hereditary kidney disease	56 (12.3)	99 (13.5)	0.56	- 0.03	88 (7.5)	113 (6.0)	0.12	0.06
Congenital diseases	24 (5.3)	29 (4.0)	0.28	0.06	22 (1.9)	24 (1.3)	0.20	0.05
Vascular diseases	38 (8.4)	52 (7.1)	0.42	0.05	220 (18.6)	346 (18.4)	0.89	0.01
Sec. glomerular disease	30 (6.6)	42 (5.7)	0.54	0.04	107 (9.1)	147 (7.8)	0.23	0.04
Diabetic kidney disease	41 (9.0)	86 (11.7)	0.14	- 0.09	260 (22.0)	421 (22.4)	0.79	- 0.01
Other	98 (21.6)	168 (22.9)	0.59	- 0.03	213 (18.0)	374 (19.9)	0.20	- 0.05
Unknown	66 (14.5)	85 (11.6)	0.14	0.09	93 (7.9)	140 (7.5)	0.67	0.02
Dialysis duration, years	-	-	-	-	3 (1, 7)	3 (1, 5)	0.10	0.13
Transplant duration, n (%)			0.49	0.07				
< 1 year	33 (7.2)	49 (6.6)			-	-	-	-
1-5 years	170 (37.2)	304 (40.7)			-	-	-	-
> 5 years	250 (54.7)	389 (52.1)			-	-	-	-
Medications^b, n (%)								
Immunosuppressants			0.58	- 0.01				
Monotherapy	14 (3.1)	19 (2.6)			-	-	-	-
Dual therapy	152 (33.6)	232 (31.4)			-	-	-	-
Continued								

	Kidney transplant recipients (N = 1204)				Dialysis patients (N = 3206)			
	Women (N = 457)	Men (N = 747)	p-value	Std. difference	Women (N = 1225)	Men (N = 1981)	p-value	Std. difference
Triple therapy	286 (63.3)	489 (66.1)			–	–	–	–
RAAS inhibitors	142 (35.9)	281 (44.5)	0.01	– 0.18	209 (23.4)	439 (30.8)	< 0.001	– 0.17
Disease characteristics								
Presenting symptoms, n (%)								
Sore throat	82 (19.2)	112 (16.5)	0.26	0.07	140 (14.6)	192 (13.0)	0.25	0.05
Cough	265 (60.2)	438 (61.5)	0.66	0.03	471 (47.0)	765 (48.9)	0.36	0.04
Shortness of breath	168 (38.1)	297 (41.9)	0.20	0.08	318 (31.6)	502 (32.0)	0.81	0.01
Fever	281 (63.3)	497 (69.5)	0.03	0.13	506 (50.3)	873 (55.6)	0.01	0.16
Headache	106 (25.1)	140 (21.0)	0.12	0.10	131 (13.7)	122 (8.3)	< 0.001	0.18
Nausea or vomiting	89 (20.7)	84 (12.3)	< 0.001	0.23	133 (13.5)	151 (9.8)	0.004	0.12
Diarrhoea	124 (28.7)	177 (25.8)	0.28	0.07	132 (13.3)	196 (12.8)	0.68	0.02
Myalgia or arthralgia	135 (31.8)	208 (31.3)	0.88	0.01	214 (22.3)	322 (21.7)	0.74	0.01
Vital signs								
Temperature, °C	37.6 (1.1)	37.5 (1.1)	0.30	0.07	37.3 (1.0)	37.5 (1.0)	0.001	– 0.15
Respiration rate, /min	20.5 (6.6)	21.0 (7.3)	0.30	– 0.07	18.4 (4.8)	18.6 (5.1)	0.35	– 0.04
O ₂ saturation room air, %	94.3 (6.4)	93.9 (6.6)	0.36	0.06	94.1 (5.1)	93.7 (5.8)	0.16	0.06
Systolic BP, mm Hg	132.0(21.9)	133.5 (21.0)	0.37	– 0.07	137.0 (25.0)	136.3 (25.9)	0.54	0.03
Diastolic BP, mm Hg	77.8 (14.2)	78.4 (13.9)	0.60	– 0.04	73.4 (15.0)	73.6 (15.5)	0.85	– 0.01
Pulse rate, BPM	89.0 (16.7)	86.3 (16.9)	0.04	0.16	80.2 (14.2)	81.8 (16.0)	0.03	– 0.11
Laboratory test results								
eGFR, ml/min/1.73m ²	41.7 (23.8)	42.9 (23.7)	0.59	– 0.05	–	–	–	–
Lymphocytes, ×1000/μL	0.8 (0.5, 1.3)	0.8 (0.5, 1.3)	0.60	– 0.06	0.9 (0.6, 1.3)	0.9 (0.6, 1.3)	0.46	0.01
CRP, mg/L	72 (25, 147)	83 (33, 187)	0.05	– 0.14	68 (20, 190)	82 (27, 240)	0.03	– 0.15

Table 1. Baseline characteristics by sex in kidney transplant recipients and dialysis patients with COVID-19. Continuous variables are reported as mean (standard deviation) or median (interquartile interval). Groups were compared using independent sample t-test, Mann–Whitney U-test, or Pearson Chi-square test as appropriate. Obesity is defined as BMI > 30 kg/m². Std., standardized; °C, degree Celsius; O₂, oxygen; BP, blood pressure; BPM, beats per minute; eGFR, estimated glomerular filtration rate; CRP, C-reactive protein; RAAS = Renin–angiotensin–aldosterone system. ^aTotal number may not add up due to missingness (126 missing in kidney transplant recipients, 751 missing in dialysis patients). ^bIn those hospitalized.

Studies in the early phase of the pandemic that investigated the sex-mortality relationship among kidney transplant recipients were relatively small and reported no difference in mortality between men and women. However, it remained unclear whether men and women continued to exhibit a similar risk of mortality as more data accumulated. A recent large retrospective study among solid organ transplant recipients suggested a 47% higher risk of mortality in men compared with women in kidney transplant recipients when accounting for differences in patient characteristics⁵. Unfortunately, due to the retrospective nature, this study had a considerable number of missing records for comorbidities and due to miscoding, a substantial number of these patients may have been misclassified as not having comorbidity. It is worth noting that in the case of other infectious diseases, such as influenza, where men are reported to have an increased risk of mortality in the general population^{21,22}, sex has also been reported not to be associated with mortality in immunocompromised study populations²³.

The use of immunosuppressants may be one of the reasons for the lack of difference in risk of mortality between men and women in kidney transplant recipients with COVID-19. Previously it has been demonstrated that in the general population with COVID-19, men have increased plasma levels of innate immune cytokines such as IL-8 and IL-18 along with more robust induction of monocytes, whereas women show more robust T cell activation compared with men². This study also demonstrated that higher levels of innate immune cytokines and poor T-cell response were associated with poor outcomes, suggesting a more robust immune response to COVID-19 potentially contributes to the survival advantage among women². However, among kidney transplant recipients, which typically are on maintenance immunosuppression, any survival advantage due to a robust immune response may be mitigated.

Transplant recipients (N = 1204)	Women (N = 457)	Men (N = 747)	
Event, n (%)	85 (18.6)	126 (16.9)	p-value
Model 1	Ref.	0.90 (0.68, 1.18)	0.43
Model 2	Ref.	0.97 (0.73, 1.29)	0.86
Model 3	Ref.	0.96 (0.73, 1.28)	0.80
Model 4	Ref.	0.87 (0.63, 1.19)	0.37
Model 5	Ref.	0.89 (0.65, 1.23)	0.49
Dialysis patients (N = 3206)	Women (N = 1225)	Men (N = 1,981)	
Event, n (%)	268 (21.9)	536 (27.1)	p-value
Model 1	Ref.	1.27 (1.10, 1.47)	0.001
Model 2	Ref.	1.41 (1.21, 1.64)	<0.001
Model 3	Ref.	1.40 (1.20, 1.63)	<0.001
Model 4	Ref.	1.32 (1.13, 1.56)	0.001
Model 5	Ref.	1.33 (1.13, 1.56)	0.001

Table 2. Association of sex with 3-month mortality in kidney transplant recipients and dialysis patients with COVID-19 (presented are hazard ratios with 95% confidence intervals). Model 1: crude. Model 2: Model 1 + age (continuous), clinical frailty score (continuous). Model 3: Model 2 + the reason for COVID-19 screening (symptoms-based screening, positive COVID-19 contact or routine screening). Model 4: Model 3 + smoking (never, current, former), obesity (yes/no), hypertension (yes/no), diabetes (yes/no), heart failure (yes/no), chronic lung disease (yes/no), coronary artery disease (yes/no), and auto-immune disease (yes/no). Model 5: Model 4 + duration of kidney function replacement therapy (years) and estimated glomerular filtration rate (continuous). (p-for interaction between sex and type of kidney function replacement therapy = 0.02 in fully adjusted model for 3 month mortality).

Among dialysis patients with COVID-19, our results are in line with other larger studies published later in the COVID-19 pandemic which also showed an increased risk of mortality in men compared with women^{8,9}. Earlier studies, however, did not specifically aim to investigate the sex-mortality relationship and lacked careful control of factors that may explain the excess risk of mortality among men^{6–9,24}. Consequently, it was unclear whether the association between sex and mortality in dialysis patients was independent of potential sex differences in comorbidities and high-risk behaviours including those related to access to health care. Our study demonstrated that the association between sex and mortality persists independent of comorbidities and factors related to healthcare access, and in our study, we additionally accounted for clinical frailty score and potential sex differences in the time from symptom(s) onset to clinical presentation to limit the possibility of residual influence from comorbidities and factors related to health care access.

Dialysis patients have impaired immune function which may influence the sex-mortality relationship in this population compared with the general population when infected with COVID-19. Among dialysis patients in our study, the risk of mortality was about 30% higher in men compared with women. In the general population with COVID-19, a meta-analysis including 92 studies and 3,111,714 subjects reported an almost 40% higher likelihood of mortality in men¹. When this analysis was repeated after accounting for reporting bias, the likelihood of mortality in men was estimated to be even about 64% higher in men compared with women. Other studies in the general population with COVID-19 that were not included in the aforementioned meta-analysis, with similar mean age and design as our study, reported an almost twofold higher adjusted risk of mortality in men compared with women²⁵. These mortality risks appear higher than the 1.39 increased mortality risk that we found in male versus female patients on dialysis. These data suggest that the sex difference in mortality risk among dialysis patients may be narrower compared to the sex difference in mortality risk among the general population with COVID-19.

Our results also demonstrated that the absolute risk of mortality is lower in kidney transplant recipients compared with dialysis patients. However, it should be noted that after adjustment for differences in age, frailty, and comorbidities between these two patient groups, the risk of mortality is actually higher among kidney transplant recipients compared with dialysis patients²⁰. Differences in risk of mortality by type of KFRT and sex were apparent when we analyzed male–female kidney transplant recipients and dialysis patients together in one combined dataset (Table S6).

Our findings imply that sex may be an important factor in the management of patients on KFRT with COVID-19. Male dialysis patients should be informed about their higher risk of complications compared with females when infected with COVID-19 and be advised when in doubt to seek medical attention in the case of (suspected) COVID-19.

The present study has a number of strengths. This study includes detailed information on key patient and disease characteristics and prospective information on mortality from a large number of dialysis patients and kidney transplant recipients with COVID-19, which allowed a comprehensive assessment of the sex-mortality association including a direct comparison of the sex-mortality relationship between kidney transplant recipients and dialysis patients. This study was also able to investigate the association between sex and mortality by





Figure 1. Percentage mortality by sex and type of kidney function replacement therapy (A) and hazard ratio for the association of sex (male vs. female (reference)) with 3-month mortality by type of kidney function replacement therapy (B). *Adjusted for: age (continuous), clinical frailty score (continuous), the reason for COVID-19 screening (symptoms-based screening, positive COVID-19 contact or routine screening), smoking (never, current, former), obesity (yes/no), hypertension (yes/no), diabetes (yes/no), heart failure (yes/no), chronic lung disease (yes/no), coronary artery disease (yes/no), and auto-immune disease (yes/no), duration of kidney function replacement therapy (years) and estimated glomerular filtration rate (continuous). †Adjusted estimate from literature (Nat Commun 2020: <https://pubmed.ncbi.nlm.nih.gov/33298944/>).

reason for COVID-19 screening which is particularly relevant given the sex difference in health care seeking behaviour^{16–18}. However, this study also has limitations. First, we did not collect the information on viral load. Therefore, we were not able to investigate whether males and females differed in their viral load. Second, we only had data available from patients infected with wild-type or early variants of COVID-19 (e.g. alpha and delta)²⁶. To our knowledge, there has also been no evidence that one viral strain/mutation affected the sex difference in mortality risk more than others. Moreover, data in our study were collected before mass vaccination was rolled out and before the efficacy of any of the currently known pharmacological treatments (e.g. steroid, remdesivir, and/or tocilizumab) was established. This allowed us to investigate the sex-mortality association in a homogeneous population that is unlikely to be influenced by any possible sex difference in vaccination rate or response, or in medication use or efficacy. Third, given the observational nature of the study design it was not possible to reliably investigate whether the dose and/or type of immunosuppressant influenced the sex-mortality relationship among kidney transplant recipients. Fourth, because reporting was voluntary, the included patients

A) Kidney transplant recipients



B) Dialysis patients




Figure 2. Association of sex with 3-month mortality in kidney transplant recipients (A) and dialysis patients (B) with COVID-19 by key subgroups (presented are hazard ratios for male versus female with 95% confidence intervals, and p-values for interaction).

Men (N = 2728)	Dialysis patients (N = 1981)	Kidney transplant recipients (N = 747)	p-value
Event, n (%)	536 (27.1)	126 (16.9)	
Model 1	Ref.	0.57 (0.47, 0.69)	<0.001
Model 2	Ref.	1.25 (1.01, 1.55)	0.04
Model 3	Ref.	1.19 (0.96, 1.47)	0.13
Model 4	Ref.	1.20 (0.97, 1.50)	0.09
Model 5	Ref.	1.39 (1.02, 1.89)	0.04
Women (N = 1682)	Dialysis patients (N = 1225)	Kidney transplant recipients (N = 457)	p-value
Event, n (%)	268 (21.9)	85 (18.6)	
Model 1	Ref.	0.81 (0.63, 1.03)	0.09
Model 2	Ref.	1.63 (1.25, 2.13)	<0.001
Model 3	Ref.	1.54 (1.17, 2.01)	0.002
Model 4	Ref.	1.64 (1.24, 2.17)	0.001
Model 5	Ref.	2.04 (1.40, 2.97)	<0.001

Table 3. Association of type of renal replacement therapy (kidney transplant vs dialysis) with 3-month mortality in men (upper panel) and women (lower panel) with COVID-19 (presented are hazard ratios with 95% confidence intervals). Model 1: crude. Model 2: Model 1 + age (continuous), clinical frailty score (continuous). Model 3: Model 2 + the reason for COVID-19 screening (symptoms-based screening/positive COVID-19 contact or routine screening). Model 4: Model 3 + smoking (never, current, former), obesity (yes/no), hypertension (yes/no), diabetes (yes/no), heart failure (yes/no), chronic lung disease (yes/no), coronary artery disease (yes/no), and auto-immune disease (yes/no). Model 5: Model 4 + duration of kidney function replacement therapy (years) and estimated glomerular filtration rate (continuous). (p-for interaction between sex and type of kidney function replacement therapy = 0.02 in fully adjusted model for 3 month mortality).

may not be completely representative of the overall population of KFRT patients with COVID-19. However, it should be noted that COVID-19 case-fatality rates and relative risk of mortality among men (vs. women) among dialysis patients in our study are comparable to those reported in KFRT registry studies that include non-selected populations, but lack detailed information for adjustment as we have in our study⁹.

In conclusion, among patients on KFRT with COVID-19, the male sex is not a risk factor for mortality in kidney transplant recipients but remains a risk factor in dialysis patients. The use of immunosuppressants in kidney transplant recipients, among other factors, may have narrowed the difference in the immune response to COVID-19 between men and women, and therefore reduced the sex difference in the risk of COVID-19 mortality.

Data availability

The dataset analysed during the current study is available from the corresponding author on reasonable request.

Received: 28 July 2022; Accepted: 18 October 2022

Published online: 26 October 2022

References

1. Peckham, H. *et al.* Male sex identified by global COVID-19 meta-analysis as a risk factor for death and ITU admission. *Nat. Commun.* **11**(1), 6317 (2020).
2. Takahashi, T. *et al.* Sex differences in immune responses that underlie COVID-19 disease outcomes. *Nature* **588**(7837), 315–320 (2020).
3. Cravedi, P. *et al.* COVID-19 and kidney transplantation: Results from the TANGO International Transplant Consortium. *Am. J. Transplant.* **20**(11), 3140–3148 (2020).
4. Kremer, D. *et al.* A systematic review and meta-analysis of COVID-19 in kidney transplant recipients: Lessons to be learned. *Am. J. Transplant.* **21**(12), 3936–3945 (2021).
5. Vinson, A. J. *et al.* Sex and organ-specific risk of major adverse renal or cardiac events in solid organ transplant recipients with COVID-19. *Am. J. Transplant.* **22**(1), 245–259 (2022).
6. Haarhaus, M. *et al.* Risk prediction of COVID-19 incidence and mortality in a large multi-national hemodialysis cohort: Implications for management of the pandemic in outpatient hemodialysis settings. *Clin. Kidney J.* **14**(3), 805–813 (2021).
7. De Meester, J. *et al.* Incidence, characteristics, and outcome of COVID-19 in adults on kidney replacement therapy: A Regionwide Registry Study. *J. Am. Soc. Nephrol.* **32**(2), 385–396 (2021).
8. Salerno, S. *et al.* COVID-19 risk factors and mortality outcomes among medicare patients receiving long-term dialysis. *JAMA Netw. Open.* **4**(11), e2135379 (2021).
9. Jager, K. J. *et al.* Results from the ERA-EDTA Registry indicate a high mortality due to COVID-19 in dialysis patients and kidney transplant recipients across Europe. *Kidney Int.* **98**(6), 1540–1548 (2020).
10. Caughey, A. B. *et al.* USPSTF approach to addressing sex and gender when making recommendations for clinical preventive services. *JAMA* **326**(19), 1953–1961 (2021).
11. Noordzij, M. *et al.* ERACODA: The European database collecting clinical information of patients on kidney replacement therapy with COVID-19. *Nephrol. Dial. Transplant.* **35**, 2023–2025 (2020).
12. Harris, P. A. *et al.* The REDCap consortium: Building an international community of software partners. *J. Biomed. Inform.* **95**, 103208 (2019).

13. Rockwood, K. *et al.* A global clinical measure of fitness and frailty in elderly people. *CanMed. Assoc. J.* **173**, 489–495 (2005).
14. Nguyen, T. L. & Xie, L. Incomparability of treatment groups is often blindly ignored in randomised controlled trials—A post hoc analysis of baseline characteristic tables. *J. Clin. Epidemiol.* **130**, 161–168 (2021).
15. Lovakov, A. & Agadullina, E. R. Empirically derived guidelines for effect size interpretation in social psychology. *Eur. J. Soc. Psychol.* **3**, 485–504 (2021).
16. Mauvais-Jarvis, F. *et al.* Sex and gender: Modifiers of health, disease, and medicine. *Lancet* **396**(10250), 565–582 (2020).
17. Regitz-Zagrosek, V. Sex and gender differences in health. Science & Society Series on Sex and Science. *EMBO Rep.* **13**(7), 596–603 (2012).
18. Spagnolo, P. A., Manson, J. E. & Joffe, H. Sex and gender differences in health: What the COVID-19 pandemic can teach us. *Ann. Intern. Med.* **173**(5), 385–386 (2020).
19. Williamson, E. J. *et al.* Factors associated with COVID-19-related death using OpenSAFELY. *Nature* **584**(7821), 430–436 (2020).
20. Goffin, E. *et al.* COVID-19-related mortality in kidney transplant and haemodialysis patients: A comparative, prospective registry-based study. *Nephrol. Dial. Transplant.* **36**(11), 2094–2105 (2021).
21. Quandelacy, T. M., Viboud, C., Charu, V., Lipsitch, M. & Goldstein, E. Age- and sex-related risk factors for influenza-associated mortality in the United States between 1997–2007. *Am. J. Epidemiol.* **179**(2), 156–167 (2014).
22. <https://www.cdc.gov/mmwr/volumes/70/wr/mm7012a5.htm> (Accessed 21 May 2022).
23. Chen, L., Han, X., Li, Y., Zhang, C. & Xing, X. The severity and risk factors for mortality in immunocompromised adult patients hospitalized with influenza-related pneumonia. *Ann. Clin. Microbiol. Antimicrob.* **20**(1), 55 (2021).
24. Hilbrands, L. B. *et al.* COVID-19-related mortality in kidney transplant and dialysis patients: results of the ERACODA collaboration. *Nephrol. Dial. Transplant.* **35**(11), 1973–1983 (2020).
25. Bhopal, S. S. & Bhopal, R. Sex differential in COVID-19 mortality varies markedly by age. *Lancet* **396**(10250), 532–533 (2020).
26. <https://www.who.int/activities/tracking-SARS-CoV-2-variants> (Accessed 5 Oct 2022).

Acknowledgements

The ERACODA collaboration is an initiative to study prognosis and risk factors for mortality due to COVID-19 in patients with a kidney transplant or on dialysis that is endorsed by the ERA-EDTA. ERACODA is an acronym for European Renal Association COVID-19 Database. The organizational structure contains a Working Group assisted by a Management Team and an Advisory Board. The ERACODA Working Group members: Franssen CFM, Gansevoort RT (coordinator), Hemmelder MH, Hilbrands LB and Jager KJ. The ERACODA Management Team members: Duivenvoorden R, Noordzij M and Vart P. The ERACODA Advisory Board members: Abramowicz D, Basile C, Covic A, Crespo M, Massy ZA, Mitra S, Petridou E, Sanchez JE, White C. We thank all people that entered information in the ERACODA database for their participation, and especially all healthcare workers that have taken care of the included COVID-19 patients. The abstract of this manuscript was presented at the European Renal Association Conference 2022 and has been published in the Nephrology, Dialysis, and Transplantation journal (<https://doi.org/10.1093/ndt/gfac095.003>). The manuscript has not been submitted for consideration elsewhere.

Author contributions

All authors contributed to the data collection, study design, data analysis, interpretation, and drafting of this paper.

Funding

Unrestricted research grants were obtained from the European Renal Association, The Dutch Kidney Foundation, Baxter, and Sandoz. Neither organization had any role in the design of the study, interpretation of results, nor in writing of the article.

Competing interests

The authors declare no competing interests.

Additional information

Supplementary Information The online version contains supplementary material available at <https://doi.org/10.1038/s41598-022-22657-4>.

Correspondence and requests for materials should be addressed to P.V.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2022

ERACODA Collaborators

Jeroen B. van der Net¹³, Marie Essig¹⁴, Peggy W. G. du Buf-Vereijken¹⁵, Betty van Ginneken¹⁵, Nanda Maas¹⁵, Brigit C. van Jaarsveld¹⁶, Frederike J. Bemelman¹⁶, Farah Klingenberg-Salahova¹⁶, Frederiek Heenan-Vos¹⁶, Marc G. Vervloet¹⁶, Azam Nurmohamed¹⁶, Liffert Vogt¹⁶, Daniel Abramowicz¹⁷, Sabine Verhofstede¹⁷, Omar Maoujoud¹⁸, Thomas Malfait¹⁹, Jana Fialova²⁰, Edoardo Melilli²¹, Alexandre Favà²¹, Josep M. Cruzado²¹, Nuria Montero Perez²¹, Joy Lips²², Harmen Krepel²³, Harun Adilovic²⁴, Daniela Radulescu^{25,26}, Maaïke Hengst²⁷, Constantijn Konings²⁷, Andrzej Rydzewski²⁸, Philippe Braconnier²⁹, Daniel Weis²⁹, Ryszard Gellert³⁰, João Oliveira³¹, Daniela G. Alferes³², Elena V. Zakharova³³, Patrice Max Ambühl³⁴, Rebecca Guidotti³⁴, Andrea Walker³⁴, Fanny Lepeytre³⁵, Clémentine Rabaté³⁵, Guy Rostoker³⁵, Sofia Marques³⁶, Tijana Azasevac³⁷, Gordana Strazmester Majstorovic³⁷, Dajana Katicic³⁸, Marc ten Dam³⁹, Thilo Krüger⁴⁰, Szymon Brzosko⁴¹, Vassilios Liakopoulos⁴², Adriaan L. Zanen⁴³, Susan J. J. Logtenberg⁴⁴, Lutz Fricke⁴⁵, Olexandr Kuryata⁴⁶, Jeroen J. P. Slebe⁴⁷, Samar Abd ElHafeez⁴⁸, Delphine Kemlin⁴⁹, Jacqueline van de Wetering⁵⁰, Marlies E. J. Reinders⁵⁰, Dennis A. Hesselink⁵⁰, J. Kal-van Gestel⁵⁰, Jaromir Eiselt⁵¹, Lukas Kielberger⁵¹, Hala S. El-Wakil⁵², Martine Verhoeven⁵³, Ian Logan⁵⁴, Cristina Canal⁵⁵, Carme Facundo⁵⁵, Ana M. Ramos⁵⁶, Alicja Debska-Slizien⁵⁷, Noline M. H. Veldhuizen⁵⁸, Eirini Tigka⁵⁹, Maria Anna Polyzou Konsta⁶⁰, Stylianos Panagoutsos⁶¹, Francesca Mallamaci⁶², Adele Postorino⁶², Francesco Cambareri⁶², Irina Matceac^{5,6}, Ionut Nistor^{5,6}, J. H. M. Groeneveld⁶³, Jolanda Jousma⁶³, Marjolijn van Buren⁶⁴, Fritz Diekmann⁶⁵, Federico Oppenheimer⁶⁵, Miquel Blasco⁶⁵, Tiago Assis Pereira⁶⁶, Augusto Cesar S. Santos Jr.⁶⁷, Carlos Arias-Cabrales⁶⁸, Marta Crespo⁶⁸, Laura Llinàs-Mallo⁶⁸, Anna Buxeda⁶⁸, Carla Burbulla Tàrrega⁶⁸, Dolores Redondo-Pachon⁶⁸, Maria Dolores Arenas Jimenez⁶⁸, Alberto Mendoza-Valderrey⁶⁸, Ana Cristina Martins⁶⁹, Catarina Mateus⁶⁹, Goncalo Alvila⁶⁹, Ivo Laranjinha⁶⁹, Julia M. Hofstra⁷⁰, Machiel A. Siezenga⁷⁰, Antonio Franco⁷¹, David Arroyo⁷², Sandra Castellano⁷², Maria Luisa Rodriguez-Ferrero⁷², Sagrario Balda Manzanos⁷³, R. Haridian Sosa Barrios⁷⁴, Wim Lemahieu⁷⁵, Karlijn Bartelet⁷⁶, Ahmet Burak Dirim⁷⁷, Erol Demir⁷⁷, Mehmet Sukru Sever⁷⁷, Aydin Turkmen⁷⁷, Seda Şafak⁷⁷, Daan A. M. J. Hollander⁷⁸, Stefan Büttner⁷⁹, Aiko P. J. de Vries⁸⁰, Soufian Meziyerh⁸⁰, Danny van der Helm⁸⁰, Marko Mallat⁸⁰, Hanneke Bouwsma⁸⁰, Sivakumar Sridharan⁸¹, Kristina Petrueliene⁸², Sharon-Rose Maloney⁸³, Iris Verberk⁸⁴, Frank M. van der Sande⁸⁵, Maarten H. L. Christiaans⁸⁵, Marc H. Hemmeler⁸⁵, N. MohanKumar⁸⁶, Marina Di Luca⁸⁷, Serhan Z. Tuğlular⁸⁸, Andrea B. Kramer⁸⁹, Charles Beerenhout⁹⁰, Peter T. Luik⁹¹, Julia Kerschbaum⁹², Martin Tiefenthaler⁹², Bruno Watschinger⁹³, Vadim A. Stepanov⁹⁴, Alexey B. Zulkarnaev⁹⁴, Kultigin Turkmen⁹⁵, Ilaria Gandolfini⁹⁶, Umberto Maggiore⁹⁶, Anselm Fliedner⁹⁷, Anders Åsberg⁹⁸, Geir Mjoen⁹⁸, Hitoshi Miyasato⁹⁹, Carola W. H. de Fijter¹⁰⁰, Nicola Mongera¹⁰¹, Stefano Pini¹⁰², Consuelo de Biase¹⁰³, Angele Kerckhoffs¹⁰³, Anne Els van de Logt¹⁰³, Rutger Maas¹⁰³, Luuk B. Hilbrands¹⁰³, Olga Lebedeva¹⁰⁴, Veronica Lopez¹⁰⁵, Louis J. M. Reichert¹⁰⁶, Jacobien Verhave¹⁰⁶, Denis Titov¹⁰⁷, Ekaterina V. Parshina¹⁰⁸, Luca Zanoli¹⁰⁹, Carmelita Marcantoni¹⁰⁹, Gijs van Kempen¹¹⁰, Liesbeth E. A. van Gils-Verrij¹¹¹, John C. Harty¹¹², Marleen Meurs¹¹³, Marek Myslak¹¹⁴, Yuri Battaglia¹¹⁵, Paolo Lentini¹¹⁶, Edwin den Deurwaarder¹¹⁷, Maria Stendahl¹¹⁸, Hormat Rahimzadeh¹¹⁹, Ivan Rychlik¹²⁰, Carlos J. Cabezas-Reina¹²¹, Ana Maria Roca¹²¹, Ferdau Nauta¹²², İdris Sahin¹²³, Eric Goffin¹²⁴, Nada Kanaan¹²⁴, Laura Labriola¹²⁴, Arnaud Devresse¹²⁴, Anabel Diaz-Mareque¹²⁵, Armando Coca¹²⁶, Gabriel de Arriba¹²⁷, Björn K. I. Meijers¹²⁸, Maarten Naesens¹²⁸, Dirk Kuypers¹²⁸, Bruno Desschans¹²⁸, Annelies Tonnerli¹²⁹, Karl M. Wissing¹²⁹, Ivana Dedinska¹³⁰, Giuseppina Pessolano¹³¹, Shafi Malik¹³², Evangelia Dounousi¹³³, Evangelos Papachristou¹³⁴, Stefan P. Berger¹³⁵, Jan Stephan F. Sanders¹³⁵, Casper F. M. Franssen¹³⁵, Akin Özyilmaz¹³⁵, Jadranka Buturović Ponikvar¹³⁶, Andreja Marn Pernat¹³⁶, Damjan Kovac¹³⁶, Miha Arnol¹³⁶, Robert Ekart¹³⁷, Alfesio C. Abrahams¹³⁸, Femke M. Molenaar¹³⁸, Arjan D. van Zuilen¹³⁸, Sabine C. A. Meijvis¹³⁸, Helma Dolmans¹³⁸, Ekamol Tantisattamo¹³⁹, Pasquale Esposito¹⁴⁰, Jean-Marie Krzesinski¹⁴¹, Jean Damacène Barahira¹⁴¹, Maurizio Gallieni¹⁴², Paloma Leticia Martin-Moreno¹⁴³, Gabriele Guglielmetti¹⁴⁴, Gabriella Guzzo¹⁴⁵, Nestor Toapanta¹⁴⁶, Maria Jose Soler¹⁴⁶, Antinus J. Luik¹⁴⁷, Willi H. M. van Kuijk¹⁴⁷, Lonneke W. H. Stikkelbroeck¹⁴⁷, Marc M. H. Hermans¹⁴⁷, Laurynas Rimsevicius¹⁴⁸, Marco Righetti¹⁴⁹ & Mahmud Islam¹⁵⁰

¹³Albert Schweitzer Hospital, Dordrecht, The Netherlands. ¹⁴Ambroise Pare Hospital, APHP Paris-Saclay

University, Boulogne Billancourt, France. ¹⁵Amphia Hospital, Breda, The Netherlands. ¹⁶Amsterdam UMC, Amsterdam, The Netherlands. ¹⁷Antwerp University Hospital, Antwerp, Belgium. ¹⁸Faculty of Medicine, Avicennes Military Hospital, Cadi Ayyad University, Marrakech, Morocco. ¹⁹AZ Delta, Roeselare, Belgium. ²⁰B. Braun Avitum, Litomerice, Czech Republic. ²¹Bellvitge University Hospital, Hospitalet de Llobregat, Barcelona, Spain. ²²Bernhoven Hospital, Uden, The Netherlands. ²³Bravis Hospital, Roosendaal/Bergen Op Zoom, The Netherlands. ²⁴Cantonal Hospital Zenica, Zenica, Bosnia and Herzegovina. ²⁵Carol Davila' University of Medicine and Pharmacy, Bucharest, Romania. ²⁶Emergency Clinical Hospital 'Sf. Ioan', Bucharest, Romania. ²⁷Catharina Hospital, Eindhoven, The Netherlands. ²⁸Central Clinical Hospital of the Ministry of Interior, Warsaw, Poland. ²⁹Centre Hospitalier du Nord, Ettelbruck, Luxembourg. ³⁰Centre of Postgraduate Medical Education, Warsaw, Poland. ³¹Centrodial, São João da Madeira, Portugal. ³²Centro Hospitalar Vila Nova de Gaia/Espinho, Vila Nova de Gaia, Portugal. ³³City Hospital N.a. S.P. Botkin, Moscow, Russia. ³⁴City Hospital Zürich, Zurich, Switzerland. ³⁵Claude Galien Hospital Ramsay Santé, Quincy-Sous-Sénart, France. ³⁶Clínica de Hemodiálise de Felgueiras, Felgueiras, Portugal. ³⁷Clinical Centre of Vojvodina & Faculty of Medicine Novi Sad, University of Novi Sad, Novi Sad, Serbia. ³⁸Croatian Society of Nephrology, Dialysis and Transplantation, Zagreb, Croatia. ³⁹CWZ Nijmegen, Nijmegen, The Netherlands. ⁴⁰DaVita Geilenkirchen, Geilenkirchen, Germany. ⁴¹DaVita, Wrocław, Poland. ⁴²1st Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece. ⁴³Deventer Ziekenhuis, Deventer, The Netherlands. ⁴⁴Dianet Dialysis Center, Utrecht, The Netherlands. ⁴⁵Dialysis Center Bochum, Bochum, Germany. ⁴⁶Dnipro State Medical University, Dnipro, Ukraine. ⁴⁷Elyse Klinieken Voor Nierzorg, Kerkrade, The Netherlands. ⁴⁸Epidemiology Department, High Institute of Public Health-Alexandria University, Alexandria, Egypt. ⁴⁹Erasmus Hospital, Brussels, Belgium. ⁵⁰Department of Internal Medicine, Erasmus MC Transplant Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands. ⁵¹Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic. ⁵²Faculty of Medicine-Alexandria University, Alexandria, Egypt. ⁵³Franciscus Gasthuis & Vlietland, Schiedam, The Netherlands. ⁵⁴Freeman Hospital, Newcastle Upon Tyne, UK. ⁵⁵Fundació Puigvert, Barcelona, Spain. ⁵⁶Fundación Jiménez Díaz, Madrid, Spain. ⁵⁷Gdansk Medical University, Gdansk, Poland. ⁵⁸Gelre Hospital, Apeldoorn, The Netherlands. ⁵⁹General Hospital of Athens "G. Gennimatas", Athens, Greece. ⁶⁰General Hospital of Serres, Serres, Greece. ⁶¹General University Hospital of Alexandroupolis, Alexandroupolis, Greece. ⁶²Grande Ospedale Metropolitano and CNR, Reggio Calabria, Italy. ⁶³Haaglanden Medisch Centrum, The Hague, The Netherlands. ⁶⁴Haga Hospital, The Hague, The Netherlands. ⁶⁵Hospital Clínic de Barcelona, Barcelona, Spain. ⁶⁶Hospital Curry Cabral-Central Lisbon University Hospital Center, Lisbon, Portugal. ⁶⁷Hospital das Clinicas, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil. ⁶⁸Hospital del Mar, Barcelona, Spain. ⁶⁹Hospital de Santa Cruz, Centro Hospitalar de Lisboa Ocidental, Lisbon, Portugal. ⁷⁰Hospital Gelderse Valleij, Ede, The Netherlands. ⁷¹Hospital General of Alicante, Alicante, Spain. ⁷²Hospital General Universitario Gregorio Marañón, Madrid, Spain. ⁷³Hospital Obispo Polanco, Salud Aragón, Spain. ⁷⁴Hospital Universitario Ramón y Cajal, Madrid, Spain. ⁷⁵Imelda Hospital, Bonheiden, Belgium. ⁷⁶Isala, Zwolle, The Netherlands. ⁷⁷Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey. ⁷⁸Jeroen Bosch Ziekenhuis, Den Bosch, The Netherlands. ⁷⁹Klinikum Aschaffenburg-Alzenau, Aschaffenburg, Germany. ⁸⁰Leiden University Medical Center, Leiden, The Netherlands. ⁸¹Lister Hospital, Stevenage, UK. ⁸²Lithuanian University of Health Sciences, Kaunas, Lithuania. ⁸³Luzerner Kantonsspital, Luzern, Switzerland. ⁸⁴Maasstad Ziekenhuis, Rotterdam, The Netherlands. ⁸⁵Maastricht University Medical Center, Maastricht, The Netherlands. ⁸⁶Manipal Hospital, Manipal, India. ⁸⁷Marche Nord Hospital, Pesaro, Italy. ⁸⁸Marmara University School of Medicine, Istanbul, Turkey. ⁸⁹Martini Ziekenhuis, Groningen, The Netherlands. ⁹⁰Maxima Medisch Centrum, Veldhoven, The Netherlands. ⁹¹Meander Medisch Centrum, Amersfoort, The Netherlands. ⁹²Medical University Innsbruck, Innsbruck, Austria. ⁹³Medical University of Vienna, Vienna, Austria. ⁹⁴Moscow Regional Research and Clinical Institute, Moscow, Russia. ⁹⁵Necmettin Erbakan University Meram School of Medicine, Konya, Turkey. ⁹⁶Nephrology Unit, Department of Medicine and Surgery, University of Parma, Parma, Italy. ⁹⁷Nierenzentrum Reutlingen-Tübingen, Reutlingen, Germany. ⁹⁸Norwegian Renal Registry, Oslo University Hospital-Rikshospitalet, Oslo, Norway. ⁹⁹Okinawa Chubu Hospital, Uruma, Japan. ¹⁰⁰OLVG, Amsterdam, The Netherlands. ¹⁰¹Ospedale S. Maurizio Bolzano, Bolzano, Italy. ¹⁰²Padua University Hospital, Padua, Italy. ¹⁰³Radboud University Medical Center, Nijmegen, The Netherlands. ¹⁰⁴Regional Clinical Hospital, Yaroslavl, Russia. ¹⁰⁵Regional Hospital of Malaga, Malaga, Spain. ¹⁰⁶Rijnstate Hospital, Arnhem, The Netherlands. ¹⁰⁷RUDN University, Moscow, Russia. ¹⁰⁸Saint-Petersburg State University Hospital, Saint-Petersburg, Russia. ¹⁰⁹San Marco Hospital, University of Catania, Catania, Italy. ¹¹⁰Saxenburgh Medisch Centrum, Hardenberg, The Netherlands. ¹¹¹Sint Antonius Ziekenhuis, Nieuwegein, The Netherlands. ¹¹²Southern Health and Social Care Trust, Newry, Northern Ireland. ¹¹³Spaarne Gasthuis, Haarlem, The Netherlands. ¹¹⁴SPWSZ Hospital, Szczecinie, Poland. ¹¹⁵St. Anna University Hospital, Ferrara, Italy. ¹¹⁶St. Bassiano Hospital, Bassano del Grappa, Italy. ¹¹⁷Streekziekenhuis Koningin Beatrix, Winterswijk, The Netherlands. ¹¹⁸Swedish Renal Registry, Jönköping, Sweden. ¹¹⁹Tehran University of Medical Sciences, Tehran, Iran. ¹²⁰Third Faculty of Medicine, Charles University, and Faculty Hospital Kralovske Vinohrady, Prague, Czech Republic. ¹²¹Toledo University Hospital, Toledo, Spain. ¹²²Treant/Scheper Ziekenhuis, Emmen, The Netherlands. ¹²³Turgut Ozal Medical Center, Malatya, Turkey. ¹²⁴Université Catholique de Louvain, Cliniques Universitaires St Luc, Brussels, Belgium. ¹²⁵University Clinical Hospital of Santiago de Compostela, Santiago de Compostela, Spain. ¹²⁶University Clinical Hospital of Valladolid, Valladolid, Spain. ¹²⁷University Hospital of Guadalajara, Guadalajara, Spain. ¹²⁸University Hospital Leuven, Leuven, Belgium. ¹²⁹University Hospital Brussels, Brussels, Belgium. ¹³⁰University Hospital Martin and Jessenius Faculty of Medicine Comenius University, Martin, Slovakia. ¹³¹University Hospital Medical Center Verona, Verona, Italy. ¹³²University Hospitals of Coventry and Warwickshire NHS Trust, Coventry, UK. ¹³³University Hospital of Ioannina, Ioannina, Greece. ¹³⁴University Hospital of Patras, Patras, Greece. ¹³⁵University Medical Center Groningen, Groningen, The Netherlands. ¹³⁶University Medical Center Ljubljana, Ljubljana, Slovenia. ¹³⁷University Medical Centre Maribor, Maribor, Slovenia. ¹³⁸University Medical Center Utrecht, Utrecht, The Netherlands. ¹³⁹University of California Irvine School of Medicine, Orange, CA, USA. ¹⁴⁰University of Genoa, Genoa, Italy. ¹⁴¹University of Liège, Liège, Belgium. ¹⁴²University of Milan, Milan, Italy. ¹⁴³University of Navarra Clinic, Pamplona, Spain. ¹⁴⁴University of Piemonte

Oriente, Novara, Italy. ¹⁴⁵Valais Hospital, Sion & Lausanne University Hospital, Lausanne, Switzerland. ¹⁴⁶Vall d'Hebron University Hospital, Barcelona, Spain. ¹⁴⁷VieCuri Medical Centre, Venlo, The Netherlands. ¹⁴⁸Vilnius University, Vilnius, Lithuania. ¹⁴⁹Vimercate Hospital, Vimercate, Italy. ¹⁵⁰Zonguldak Ataturk State Hospital, Zonguldak, Turkey.